Orientina Di Giovanni

Orientina is the Head of Corporate Marketing at Zambon. She joined the company in 2006 as Strategic Planning Director and today she is responsible for marketing strategies of Primary Care and OTC global brands. Since 2013 Orientina is also leading the new CNS Franchise development, including Safinamide Go To Market Strategy – a new product for Parkinson Disease that was in-licensed in 2012 from Newron Pharmaceuticals with worldwide licensing rights (with the exception of Japan and the Far East). Before joining Zambon, Orientina worked in several industries including Strategic Consulting, Publishing and Communication. She graduated in Economics and Social Sciences at Bocconi University in Milan.